[144] Cadrenal Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Cadrenal Therapeutics, Inc. (CVKD) filed a Form 144 notifying a proposed sale of 30,600 common shares held by the filer. The shares were acquired in a private placement on 01/25/2022 and the aggregate market value of the shares to be sold is listed as $428,094.00. The form identifies Merrill Lynch (Ponte Vedra Beach, FL) as the broker and lists an approximate sale date of 08/27/2025 on the NASQ exchange. The filing states no securities were sold by the filer in the past three months and includes the standard representation that the seller is not aware of undisclosed material adverse information.

Insights

Securities Analyst

TL;DR: Routine Form 144 filing for a planned sale of 30,600 shares, reflecting a holder monetizing a private placement stake.

The filing is a standard Rule 144 notice describing an intended sale rather than evidence of completed transactions or operational changes. Key facts are explicit: 30,600 common shares acquired via private placement on 01/25/2022, aggregate market value $428,094, broker Merrill Lynch, and planned sale date 08/27/2025 on NASQ. Absence of sales in the prior three months and the seller's certification about material nonpublic information reduce near-term informational surprises. This notice is informational for market transparency but does not itself alter company fundamentals.

Corporate Governance Expert

TL;DR: Administrative disclosure of an intended insider/affiliate sale; procedural compliance with Rule 144 is documented.

The form documents compliance with Rule 144 by providing acquisition details, planned broker and sale date, and the filer’s certification regarding material nonpublic information. It identifies the original acquisition as a private placement from the company, which is relevant for establishing holding period and resale eligibility. The filing contains no signatures or dates of notice/plan adoption in the provided content, so completeness of execution elements cannot be confirmed from this extract alone.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 824 A1A North Suite 200 Ponte Vedra Beach FL 32082	30600	428094.00	2046854	08/27/2025	NASQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/25/2022	Private Placement	Company			30600	01/25/2022	Private Placement

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Cadrenal Therapeutics (CVKD) intend to sell under this Form 144?

The filer intends to sell 30,600 common shares through Merrill Lynch with an aggregate market value of $428,094.00.

When were the shares being offered for sale acquired?

The shares were acquired in a private placement on 01/25/2022.

What is the approximate date of the proposed sale listed on the filing?

The filing lists an approximate sale date of 08/27/2025 and the named exchange is NASQ.

Has the filer sold any Cadrenal Therapeutics securities in the past three months?

No. The filing states "Nothing to Report" for securities sold during the past three months.

Which broker is named to execute the sale?

The broker listed is Merrill Lynch located at 824 A1A North Suite 200, Ponte Vedra Beach, FL 32082.